contentSlug

type

ContentPage_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentPage_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  createdAt
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
  companies {
    viewerIsFollowing
    id
    name
    pageUrl
    forum {
      threadUrl
    }
    defaultInstrument {
      symbol
      id
    }
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  createdAt
  changedAt
  isPremium
  authors {
    __typename
    name
    pageUrl
    id
  }
  companies {
    name
    pageUrl
    id
  }
  tags {
    name
    id
  }
  ... on Video {
    liveTime
    videoUrl
    videoEmbedUrl(location: "inderes")
  }
  ... on Webcast {
    liveTime
    videoUrl
    videoEmbedUrl(location: "inderes")
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    summary
    companies {
      forum {
        threadUrl
        latestPosts {
          ...ForumPosts
        }
      }
      name
      id
      viewerIsFollowing
      pageUrl
      ...ExtensiveCoverage_Company
      defaultInstrument {
        isin
        id
        symbol
        marketOpen
        marketClose
        marketplace {
          region
        }
        returns {
          total
        }
      }
    }
    tags {
      viewerIsFollowing
      id
      name
      pageUrl
    }
    createdAt
    ... on Video {
      liveTime
    }
    ... on Webcast {
      liveTime
    }
    slug
    pageUrl
    ... on CompanyReport {
      reportUrl
      researchContentUrl
      researchContent {
        title
        lang
        pdfUrl
        relatedContent {
          __typename
          ...PublishingDetails
          ...Reactions
          id
        }
        content {
          title
          lang
          htmlBody
          publishedAt
          createdAt
          changedAt
          isOutdated
          isPremium
        }
      }
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
    ...ExtensiveCoverage_Snapshot
  }
  ...TrendingContent_1jQ2Cn
}

fragment ExtensiveCoverage_Company on Company {
  id
  defaultInstrument {
    estimateData {
      researchCurrency
      estimates {
        date
        recommendation
        targetPrice
      }
    }
    id
  }
}

fragment ExtensiveCoverage_Snapshot on Content {
  __isContent: __typename
  companies {
    id
    defaultInstrument {
      snapshot {
        transaction {
          date
          recommendation
          targetPrice
        }
      }
      id
    }
  }
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
            nav
            navPerShare
            opexOfNav
            quarterlySharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
            nav
            navPerShare
            opexOfNav
            quarterlySharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    name
    pageUrl
    defaultInstrument {
      priceData {
        tradeCurrency
      }
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
    id
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      name
      id
    }
    authors {
      __typename
      imgUrl
      name
      id
    }
  }
}


peptonic-medical-ab-peptonic-medical-ab-postpones-publication-of-interim-report-for-the-third-quarter

__typename

title

isPremium

lang

htmlBody

summary

companies

createdAt

pageUrl

publishers

authors

reactionGroups

translations

imgUrl

description

changedAt

Peptonic Medical is a biomedical company that conducts research and development of pharmaceuticals and medical devices in the field of women's health. The company's vision is to offer treatments for women-specific diseases and medical conditions. For example, hormone-free products are being developed for the treatment of vaginal atrophy and vaginal dryness. Peptonic Medical has its headquarters in Bromma.

Is anyone still following this company? Today, 25% of the shares have changed hands, and there was apparently some good news this morning as well. AI summary of it: Peptonic Medical AB reports it is close to the first product delivery as part of its collaboration agreement with a US-based player focused on women’s intimate wellness. The agreement covers the United States, Canada, Mexico, and the United Kingdom, and the products will be sold under the partner’s well-known brand. The first order, valued at approximately $120,000, was received in October 2025. Product design and delivery preparations have progressed as planned, and the first delivery is seen as an important milestone in Peptonic’s international growth strategy. Interim CEO Daniel Rudeklint emphasized that the collaboration strengthens the company’s opportunities to grow internationally through partnerships and to reach more women with science-based intimate care products.

STOCKHOLM (Nyhetsbyrån Direkt) Medtech company Peptonic Medical has decided to file an application for corporate restructuring. “The decision is an extraordinary measure due to a long-term strained liquidity situation and aims to create conditions for a stable and profitable business. External consultants have evaluated the situation and assessed that Peptonic has good chances of being granted reconstruction,” the company writes in a press release. Via Google Translate: STOCKHOLM (Nyhetsbyrån Direkt) Lääketieteen teknologiayritys Peptonic Medical on päättänyt jättää hakemuksen yrityssaneeraukseen. “Päätös on poikkeuksellinen toimenpide, joka johtuu pitkäaikaisen paineen aiheuttamasta likviditeettitilanteesta ja sen tavoitteena on luoda edellytykset vakaalle ja kannattavalle toiminnalle. Ulkopuoliset konsultit ovat arvioineet tilanteen ja arvioineet, että Peptonicilla on hyvät mahdollisuudet saada uudelleenjärjestely”, yhtiö kirjoittaa tiedotteessa.

I follow it every now and then. I own a small position - and based on the share price development and having read the last couple of interim reports, I don’t dare to put more money into this. Reason: In 2022, they said the company would break even in 2024.  Since then, there have been repeated share issues, and now the story is that cash flow would be positive in the second half of 2025. In 2021, they acquired a company called Common Sense from Israel. A moment ago, they announced its shutdown and gave cost reduction as the reason? Does anyone remember/can find the purchase price? It seems, however, that a loss was incurred. And are those gels applied to the labia and vaginal area really that special after all?  The company hyped up a lot in 2023 how they are expanding distribution to Central and South America, but this year no hype has been heard. I wonder why? Eh. Good luck to everyone who has put their money into this. I’m just waiting to sell some other stock so I can get out of this tracking position. I no longer believe in this company’s future. I’ll look into it again when they achieve a profitable result for at least two consecutive quarters.

I quickly found out that a new rights issue is on the way. For every current share, you would receive 4 new shares. And the price, if you then buy/exercise them, would be 0.01 SEK/share.

Is anyone still following this? I wonder what’s happening there since I don’t understand the terminology. Quite a brutal drop today.

Peptonic Medical AB (publ) (“Peptonic”) announced today that the company has agreed with the world’s largest retail chain Walmart to begin selling Peptonic’s self-test for bacterial vaginosis. The US is an important market. It is very gratifying that Walmart has decided to sell our patented self-test for bacterial vaginosis," says Erik Sundquist, CEO of Peptonic Medical. “Increasing the distribution of our products is an important part of our strategy, which makes this agreement with the world’s largest retail chain Walmart extra positive and also shows that the need for our products is great. It paves the way for rapid growth in what is already our largest market today,” says Erik Sundquist. The distribution agreement with Walmart, which has approximately 10,500 stores worldwide, of which just under 5,000 are in the United States, primarily applies to Peptonic’s patented self-test for diagnosing bacterial vaginosis. The test will be sold under Walmart’s own brand. What makes the test unique is the combination of high precision and immediate results. The distribution agreement applies to the United States and Walmart is now conducting an overview of stores currently for distribution. In Peptonic’s American organization, since the beginning of summer 2023, Angella Garcia is responsible for retail chains. Angella has extensive experience in sales to these channels in the US, but also in medtech. Through the agreement with Walmart, there is also a dialogue about the distribution of a further selection of Peptonic’s current and future products. Pharmiva’s product Vernivia will be an excellent and unique treatment solution for the self-test for bacterial vaginosis. Peptonic expects the agreement to have a positive impact on the company’s sales from 2024. Jaa että uusi jakelusopimus. Kuulostaa hyvältä, mutta menevätkö tuotteet kaupaksi loppuasiakkaille?  Entä paljonko tuotteille saadaan katetta? En oikein pääse kärrylle kokonaisuudesta.  Siemens myy Pepin tuotteita, Walmart myy samoja tuotteita. Kilpailevatko Pepin tuotteet toisiaan vastaan kahden eri jakelijan välillä?  Entä miten pakkaa sekottaa fuusioituminen Pharmivan kanssa? Toteutuuko voitollinen tulos vuonna 2024? Pohdittavaa riittää. Lisäsin hieman Pepiä salkkuuni kruunun edullisen kurssin vuoksi.

Peptonic Medical AB (publ) today announces that the Stockholm District Court has rejected the Swedish Economic Crime Authority’s (EBM) claim for a corporate fine for Peptonic of SEK 500,000. The judgment relates to the investigation of serious insider crime that Peptonic previously informed about and which are related to measures taken by the company within the framework of a financing arrangement between the company and a financial actor in the spring of 2019. At the beginning of 2022, Peptonic was informed that EBM intended to claim a corporate fine for Peptonic of SEK 500,000 due to the investigation. EBM reiterated its claim in September 2022 in connection with the former chairman, CEO and CFO of the company being charged with serious insider crime. According to the judgment from the District Court, the accused persons and the company are now acquitted on all counts. Peptonic reserved an amount corresponding to the corporate fine in its third quarter 2022 results. Peptonic intends to decide to dissolve the reserve in connection with results for the second quarter of 2023. Google translate vomit  Peptonic Medical AB (publ) announced today that the Stockholm District Court has rejected the Swedish Economic Crime Authority’s (EBM) demand for a corporate fine of SEK 500,000 for Peptonic. The judgment concerns the investigation into serious insider crime previously reported by Peptonic, which relates to measures taken by the company in the spring of 2019 within the framework of a financing arrangement between the company and a financial actor. At the beginning of 2022, Peptonic was informed that EBM intended to demand a SEK 500,000 corporate fine for Peptonic due to the investigation. EBM reiterated its demand in September 2022 when the company’s former chairman, CEO, and CFO were charged with serious insider crime. According to the District Court’s judgment, the accused and the company have now been acquitted of all charges. Peptonic reserved an amount corresponding to the corporate fine in its third-quarter 2022 results. Peptonic intends to decide on the reversal of the reserve in connection with the results for the second quarter of 2023. So the charges have been dismissed. I wonder if they will take these employees back now?

Peptonic Medical

Peptonic Medical AB (publ) (the "Company") announces a change to the publication date of its interim report for the third quarter of 2026. The publication date has been changed from November...

<div class="abstract">Peptonic Medical AB (publ) (the "Company") announces a change to the publication date of its interim report for the third quarter of 2026. The publication date has been changed from November 10, 2026, to November 26, 2026. The postponement is due to administrative reasons.</div>For further information, please contact:Daniel Rudeklint, Interim CEO Peptonic Medical AB Email: <a href="mailto:daniel.rudeklint@peptonicmedical.se">daniel.rudeklint@peptonicmedical.se</a> Phone: +46 73-158 02 73About Peptonic Medical ABPeptonic Medical AB (publ) is a Swedish women's health company that develops and markets products within intimate self-care, health and well-being. The Company's strategy is based on developing a broad product portfolio under its own brands, combined with international expansion through strategic distribution and brand partnerships.Peptonic Medical is listed on Spotlight Stock Market.<div></div>

Privacy preferences

PEPTONIC Medical AB: Peptonic Medical AB Postpones Publication of Interim Report for the Third Quarter

PEPTONIC Medical AB: Peptonic Medical AB Postpones Publication of Interim Report for the Third Quarter